Literature DB >> 10374347

Targeted diagnosis and treatment of superficial bladder cancer with monoclonal antibody BDI-1.

L Yu1, F Gu, C Zhang, S Xie, Y Guo.   

Abstract

OBJECTIVE: To explore the application of monoclonal antibody (McAb) to targeted treatment of bladder carcinoma through a series of in vitro and in vivo studies carried out in animal model and patients with bladder carcinoma.
METHODS: Monoclonal antibody BDI-1 against bladder carcinoma was prepared by the lymphocyte hybridoma technique. McAb was conjugated with 99mTc by direct reduction method. Momodin (MD) was covalently linked to McAb by SPDP method. Radioimmunoimaging of nude mice xenografts and patients with bladder carcinoma were performed with BDI-1-99mTc conjugates. An immunotoxin (BDI-1-MD) was inducted via a catheter into the bladder. Targeted treatment with BDI-1-MD was carried out in 18 patients.
RESULTS: This study showed the specificity of McAb, and clear imaging of nude mice bearing xenografts. Distribution analysis of 99mTc-BDI-1 in nude mice showed the highest value of T/NT in bladder tumor. Targeted diagnosis and treatment for patients by intravesical administration are very safe and effective.
CONCLUSION: The bladder cancer seems an ideal model for diagnostic and therapeutic approaches using regional administration of McAb conjugates via a catheter direct into the bladder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10374347

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  6 in total

1.  Transition State Structure of RNA Depurination by Saporin L3.

Authors:  Hongling Yuan; Christopher F Stratton; Vern L Schramm
Journal:  ACS Chem Biol       Date:  2016-03-08       Impact factor: 5.100

Review 2.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

Review 3.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 4.  Plant-Derived Type I Ribosome Inactivating Protein-Based Targeted Toxins: A Review of the Clinical Experience.

Authors:  David J Flavell; Sopsamorn U Flavell
Journal:  Toxins (Basel)       Date:  2022-08-18       Impact factor: 5.075

5.  Enhanced EJ Cell Killing of (125)I Radiation by Combining with Cytosine Deaminase Gene Therapy Regulated by Synthetic Radio-Responsive Promoter.

Authors:  Ling Li; Chun-li Zhang; Lei Kang; Rong-Fu Wang; Ping Yan; Qian Zhao; Lei Yin; Feng-qin Guo
Journal:  Cancer Biother Radiopharm       Date:  2015-09-18       Impact factor: 3.099

Review 6.  Engineering of Ribosome-inactivating Proteins for Improving Pharmacological Properties.

Authors:  Jia-Qi Lu; Zhen-Ning Zhu; Yong-Tang Zheng; Pang-Chui Shaw
Journal:  Toxins (Basel)       Date:  2020-03-09       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.